Takeda cuts ties to cancer drug landed in $120M Turnstone deal

Takeda is walking away from a cancer prospect it picked up in a $120 million deal. In a pipeline clear-out (PDF) that also hit narcolepsy candidate TAK-994, the Japanese drugmaker revealed it has returned the rights to oncolytic virus TAK-605 to Turnstone Biologics just 31 months after inking a deal for the drug.